Best Nasal Cancer Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

Nasal cancer is the cancer that needs the broadest surgical team in oncology. The team needs a head and neck surgical oncologist trained in skull base surgery, an ENT surgeon with endoscopic sinus and skull base surgery skills, a neurosurgeon for cases extending up to or above the skull base, a microvascular reconstructive surgeon for free flap reconstruction when large defects need to be rebuilt, an ophthalmologist or orbital surgeon when the eye is involved, a medical oncologist familiar with subtype-specific chemotherapy regimens, a radiation oncologist trained in IMRT for sinonasal cancers, a prosthodontist for fabricating the custom obturator devices that close palatal defects after maxillary surgery, and a pathologist with experience in the many sinonasal cancer subtypes. Ask for named team credentials in writing. Walk away if the hospital cannot name the combined ENT and neurosurgery team that would handle skull base cases.

Sinonasal cancers include squamous cell carcinoma, several types of adenocarcinoma, adenoid cystic carcinoma (a slow-growing subtype that spreads along nerves), olfactory neuroblastoma (also called esthesioneuroblastoma — a rare cancer arising from the smell-sensing cells), sinonasal undifferentiated carcinoma (SNUC — an aggressive subtype), mucosal melanoma (distinct from skin melanoma), sinonasal neuroendocrine carcinoma, NK/T cell lymphoma, and other rare subtypes. Each has different biology, different treatment, and very different prognosis. Accurate pathology with immunohistochemistry and, where indicated, molecular testing is essential. The tumour board reviews the pathology, MRI and CT scans, endoscopy findings, and stage to plan treatment — surgery, chemotherapy, radiation, or a combination, with the timing determined by the subtype. Walk away if treatment is recommended without a clear, named subtype diagnosis confirmed by an experienced sinonasal pathologist.

Sinonasal cancer surgery has a strong volume-outcome relationship and a steep learning curve. Modern endoscopic endonasal surgery — operating through the nostrils with high-definition cameras and specialised instruments to remove tumours without external cuts — is increasingly preferred for many cases. For tumours extending to the skull base, combined ENT and neurosurgery teams perform endoscopic skull base surgery; for the largest tumours or those extending intracranially, open anterior craniofacial resection remains necessary. Reconstruction may involve local flaps for small defects or free flap microvascular reconstruction (tissue taken from another part of the body with its blood supply attached). Ask: 'How many sinonasal cancer surgeries did your team perform last year? How many involved skull base extension or anterior craniofacial resection? What is your reconstruction success rate?' Walk away if the team cannot quote annual sinonasal surgery numbers or name the reconstruction partner for complex defects.

Nasal cancer staging needs both CT (best for assessing involvement of the bones around the sinuses and skull base) and MRI (best for soft tissue extent, involvement of the orbit and brain, and the tendency of some subtypes to spread along nerves). PET-CT is useful for advanced cases. Endoscopic examination with biopsy under image guidance provides the tissue diagnosis. Subspecialised pathology with immunohistochemistry is critical because many sinonasal cancer subtypes look similar under the microscope but have completely different treatments. Walk away if the hospital cannot explain how your specific cancer subtype was identified and how it affects your treatment plan.

Radiation for sinonasal cancer is one of the most technically demanding tasks in radiation oncology — the tumour sits within millimetres of the eye, the optic nerve (which controls vision), the brain, and other critical structures. Intensity-modulated radiotherapy (IMRT) — a precise technique that shapes the radiation dose to spare these surrounding tissues — is the modern standard. Proton beam therapy, an advanced form of radiation that uses protons instead of X-rays for even better organ-sparing, is increasingly considered for selected cases (such as paediatric patients, tumours close to the optic nerve, or re-irradiation) — though its availability in India is limited. Walk away if the hospital uses conventional 2D or 3D conformal radiation for sinonasal cancers without IMRT capability.

Beyond the surgery itself, nasal cancer care often calls on specialised procedures and rehabilitation pathways — orbital exenteration (removal of the eye) when the orbit is invaded by tumour, free flap microvascular reconstruction for large defects, and prosthodontic rehabilitation including custom obturator devices that close palatal defects after maxillectomy to allow normal eating and speech. NABH-accredited partners signal audited surgical and procedural safety. Walk away if the hospital cannot name the prosthodontic service responsible for your obturator fabrication and ongoing adjustments.

Nasal cancer treatment can be a substantial financial commitment — complex skull base or craniofacial surgery is expensive, IMRT chemoradiation adds significantly, and prosthodontic rehabilitation continues over many months. Proton beam therapy, where indicated, is significantly more expensive. A hospital that isn't empanelled for your insurance or ArogyaSri at the specific centre where your procedure happens can derail planning. Walk away if cost estimates change after admission — a serious hospital writes them down beforehand.

Nasal cancer survivors face unique long-term needs — ongoing surveillance with endoscopy and imaging because some subtypes (particularly adenoid cystic carcinoma) can recur years after treatment, prosthodontic adjustments as the obturator fit changes over time, dry eye and vision care when the eye area was treated with radiation, dry nose and chronic nasal crusting from radiation, sense of smell often permanently affected, and management of post-radiation effects on teeth and jaw. Speech and swallowing therapy when surgery involves the palate. Psychological support for facial appearance changes. You will see your team frequently. A hospital an hour away makes every visit a half-day; a network of centres close to home — same panel, same protocols, shared records — makes continuity sustainable. Walk away if you're told you must travel to one campus for every obturator adjustment and surveillance scan for the next five years.

Hospital infrastructure for nasal cancer is tiered at CION. Surveillance endoscopy, day-care chemotherapy and immunotherapy, prosthodontic obturator adjustments, speech and swallowing therapy, nutritional follow-up, and clinical reviews happen at the centre nearest your home. Endoscopic endonasal sinonasal resection, endoscopic skull base surgery, open maxillectomy, anterior craniofacial resection, free flap reconstruction, and IMRT chemoradiation run through NABH-accredited partner hospitals with verified combined head and neck oncology, ENT, and neurosurgery expertise. The same oncology team that consults at one centre stays with you across the network.

Contrast CT (with dedicated paranasal sinus protocols) and MRI (for soft tissue extent, perineural invasion, orbital and intracranial involvement) are available across six CION centres in Hyderabad. PET-CT supports staging in advanced cases. Endoscopic examination and biopsy are coordinated through partner ENT services. Subspecialised pathology — with the immunohistochemistry panels needed to differentiate the many sinonasal cancer subtypes — runs through integrated lab pathways. For rare subtypes such as NK/T lymphoma or NUT carcinoma, additional molecular testing is arranged.

Nasal cancers that involve the skull base, orbit, or brain require simultaneous expertise from multiple specialties. CION coordinates these through named partner combined surgical teams — head and neck surgical oncology, ENT skull base surgery, neurosurgery, and ophthalmology or orbital surgery — operating together where needed. The treatment plan is built around what each case actually requires, not what any single specialty can offer in isolation.

All 11 CION centres in Hyderabad have day-care infusion bays. Concurrent cisplatin chemoradiation for squamous cell carcinoma, induction chemotherapy with TPF (three-drug combination) for aggressive subtypes like SNUC, platinum + etoposide for sinonasal neuroendocrine carcinoma, distinctive regimens for NK/T lymphoma, immunotherapy (nivolumab + ipilimumab) for mucosal melanoma, and pembrolizumab or nivolumab for recurrent or metastatic squamous cell carcinoma are administered close to home. Oncology-trained nursing, on-site oncologist supervision, and protocols for managing chemotherapy side effects are standard at every centre.

Where a nasal cancer case requires endoscopic endonasal tumour resection, endoscopic skull base surgery, partial or total maxillectomy, anterior craniofacial resection combining ENT and neurosurgery, orbital exenteration when the eye is invaded by tumour, or free flap microvascular reconstruction, CION coordinates the procedure through NABH-accredited partner hospitals with established head and neck cancer programs and combined surgical capability. NABH accreditation ensures audited compliance with patient-safety, infection-control, and clinical-governance protocols.

Nasal cancer survivors face permanent changes to facial appearance, sense of smell, and (where the palate was reconstructed with an obturator) eating and speech. CION's supportive care includes prosthodontic fabrication and ongoing adjustment of obturators, speech and swallowing therapy after palatal or extensive surgery, ophthalmology care for dry eye and vision protection when the eye area was treated with radiation, dental care for radiation-affected teeth, nasal hygiene support for chronic crusting after sinus surgery and radiation, psychological support for body image concerns, and nutritional support during chemoradiation. These are coordinated within the CION network.

Every nasal cancer case at CION is reviewed by the multidisciplinary tumour board before the treatment plan is finalised. The board confirms the specific sinonasal subtype based on subspecialised pathology, debates the surgical approach (endoscopic vs open vs combined craniofacial), plans reconstruction and prosthodontic rehabilitation, decides on radiation modality and dose, plans subtype-specific chemotherapy, and decides on multidisciplinary timing. The board produces a written summary that becomes part of your records — and yours to keep. You can take it to any second opinion, anywhere.